



## SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES

0

PARTICULARS	STANDALONE				CONSOLIDATED			
	For the Quarter Ended			For the year Ended	For the Quarter Ended			For the year Ended
	30/06/2019	31/03/2019	30/06/2018	31/03/2019	30/06/2019	31/03/2019	30/06/2018	31/03/2019
	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited
<b>1 SEGMENT REVENUE :-</b>								
a) Manufacturing (CRAMS)	19,616.35	23,742.62	18,024.22	61,362.91	19,616.35	23,742.62	18,024.22	61,362.91
b) Services (DDDSS)	282.28	1,587.32	1,142.00	4,987.53	282.28	1,587.32	1,142.00	4,987.53
c) Research & Development	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>19,898.63</b>	<b>25,329.94</b>	<b>19,166.22</b>	<b>66,350.44</b>	<b>19,898.63</b>	<b>25,329.94</b>	<b>19,166.22</b>	<b>66,350.44</b>
Less Inter segment Revenue	-	-	-	-	-	-	-	-
<b>Net Sales from Operations</b>	<b>19,898.63</b>	<b>25,329.94</b>	<b>19,166.22</b>	<b>66,350.44</b>	<b>19,898.63</b>	<b>25,329.94</b>	<b>19,166.22</b>	<b>66,350.44</b>
<b>2 SEGMENT RESULTS :-</b>								
Profit/(Loss) before tax and interest:								
a) Manufacturing (CRAMS)	10,587.58	12,117.59	7,086.74	26,594.91	10,587.57	11,851.99	7,025.59	26,330.25
b) Services (DDDSS)	60.20	570.44	761.15	2,558.00	60.20	821.14	758.56	2,551.33
c) Research & Development	(1,310.15)	(1,786.89)	(1,598.88)	(6,027.60)	(4,367.88)	(4,702.99)	(2,775.79)	(11,985.07)
<b>TOTAL</b>	<b>9,337.63</b>	<b>10,901.14</b>	<b>6,249.01</b>	<b>23,125.31</b>	<b>6,279.89</b>	<b>7,970.14</b>	<b>5,008.36</b>	<b>16,896.51</b>
Less: i) Interest	46.41	69.59	35.97	199.02	84.05	69.59	35.97	199.02
ii) Other Un-allocable expenditure/(Income). net	673.06	630.50	234.77	739.99	674.55	706.24	275.91	823.17
<b>Total Profit Before Tax</b>	<b>8,618.16</b>	<b>10,201.05</b>	<b>5,978.27</b>	<b>22,186.30</b>	<b>5,521.29</b>	<b>7,194.31</b>	<b>4,696.48</b>	<b>15,874.32</b>
<b>3 SEGMENT ASSETS :</b>								
a) Manufacturing (CRAMS)	72,577.41	69,666.60	48,587.81	69,666.60	71,575.12	69,668.49	48,306.00	69,668.49
b) Services (DDDSS)	5,629.15	5,687.52	4,339.17	5,687.52	5,604.44	5,687.52	4,329.43	5,687.52
c) Research & Development	2,918.73	3,022.45	2,784.33	3,022.45	4,055.30	3,022.45	3,094.30	3,022.45
d) Un allocated	43,436.44	39,125.31	50,187.02	39,125.31	28,605.45	25,510.28	39,450.85	25,510.28
<b>TOTAL</b>	<b>124,561.73</b>	<b>117,501.88</b>	<b>105,898.33</b>	<b>117,501.88</b>	<b>109,840.31</b>	<b>103,888.74</b>	<b>95,180.58</b>	<b>103,888.74</b>
<b>SEGMENT LIABILITIES :</b>								
a) Manufacturing (CRAMS)	11,100.58	9,189.76	9,053.42	9,189.76	8,798.99	9,912.30	8,700.72	9,912.30
b) Services (DDDSS)	273.05	641.72	315.25	641.72	216.43	688.83	303.33	688.83
c) Research & Development	1,610.78	1,592.07	1,323.46	1,592.07	9,118.52	3,388.76	2,195.85	3,388.76
d) Un allocated	1,197.17	829.03	867.09	829.03	950.40	910.98	861.23	910.98
<b>TOTAL</b>	<b>14,181.58</b>	<b>12,252.58</b>	<b>11,559.22</b>	<b>12,252.58</b>	<b>19,084.34</b>	<b>14,900.87</b>	<b>12,061.13</b>	<b>14,900.87</b>

1) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th August, 2019 and the same has been reviewed by the Statutory Auditors.

2) An Investment of USD 35.00 Million, 25% stake, in Rising Holdings Inc, (formerly known as Shore Seven pharma Inc) was made during April 2019, through our wholly owned subsidiary Suven Pharma Inc. The acquisition of Assets and Liabilities are under US court supervised process of Sec 363 of U.S. Bankruptcy code. As the Assets and Liabilities valuation is under process and the business operations are yet to commence, the company did not consider Rising Holdings Inc. for the consolidation.

3) The figures for the Qtr ended 31/03/2019 are the balancing figures in respect of the full financial year and unaudited published year to date figures up to the third Qtr of the relevant financial year.

4) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD

Place: Hyderabad  
Date: 14th Aug' 2019

VENKAT JASTI  
Chairman & CEO  
DIN: 00278028